Are there Biomarkers that Predict Response to Checkpoint Inhibitors?
Yes, certain biomarkers can help predict which patients are more likely to respond to checkpoint inhibitors. For example, the presence of high levels of PD-L1 expression in tumors, mismatch repair deficiency (dMMR), and high microsatellite instability (MSI-H) are often associated with better responses to these therapies.
